drug development

A Novel Target in Schizophrenia?

by

AUT00206, a novel compound that targets potassium channels in brain interneurons, not only improves gamma oscillations in patients with schizophrenia, it also improves their symptoms, new randomized trial data suggest. In a randomized, double-blind study that included two dozen men with schizophrenia, AUT00206 compared with placebo increased the power of gamma oscillations, which were in … Read more

Sublingual Dexmedetomidine May Rapidly Calm Bipolar Agitation

by

An investigational, orally dissolving formulation film of dexmedetomidine (BXCL501, BioXcel Therapeutics) can rapidly relieve mild to moderate acute agitation in patients with bipolar disorder (BD), new research suggests. The phase 3 SERENITY II trial included almost 400 adults with bipolar I or II disorder and acute agitation. Results showed relief from acute agitation kicked in … Read more